AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17317362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3086
Study 15111524 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg
Number of subjects: 29
Study 15111524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 11236818 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-oriented care
Number of subjects: 155
Study 11236818 — intervention group
Group type: COMPARATOR
Intervention: Hospital-oriented care
Number of subjects: 155
Study 11236818 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with personality disturbance
Number of subjects: 155
Study 11236818 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 155
Study 9647568 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted Zona Hatching (AZH)
Number of subjects: 135
Study 9647568 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 135
Study 7833754 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual health education interventions
Number of subjects: 270
Study 7833754 — intervention group
Group type: EXPERIMENTAL
Intervention: Methodologically sound evaluations
Number of subjects: 270
Study 7833754 — intervention group
Group type: COMPARATOR
Intervention: Evaluations lacking random control groups
Number of subjects: 270
Study 7833754 — intervention group
Group type: COMPARATOR
Intervention: Evaluations failing to present preintervention data
Number of subjects: 270
Study 7833754 — intervention group
Group type: COMPARATOR
Intervention: Evaluations failing to present postintervention data
Number of subjects: 270
Study 7833754 — intervention group
Group type: COMPARATOR
Intervention: Evaluations omitting discussion of loss of data due to drop outs
Number of subjects: 270
Study 2147597 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin
Number of subjects: 24
Study 2147597 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 24
Study 6777807 — intervention group
Group type: EXPERIMENTAL
Intervention: IV diazepam (DZ) with N-desmethyldiazepam (NDDZ)
Number of subjects: 12
Study 6777807 — intervention group
Group type: COMPARATOR
Intervention: IV diazepam (DZ) without N-desmethyldiazepam (NDDZ)
Number of subjects: 12
Study 30264480 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-induced hypoglycaemia
Number of subjects: 45
Study 28886437 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg apple polyphenols (AE)
Number of subjects: 25
Study 28886437 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg apple polyphenols + 600 mg blackcurrant anthocyanins (AE+BE)
Number of subjects: 25
Study 28886437 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (CON)
Number of subjects: 25
Study 26635453 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.02% mitomycin C four times a day for five days
Number of subjects: 132
Study 26635453 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.05% cyclosporine four times a day for three months
Number of subjects: 132
Study 26635453 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 2.5% bevacizumab four times a day for three months
Number of subjects: 132
Study 26635453 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears four times a day for three months (Control group)
Number of subjects: 132
Study 23466591 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate 5 g daily
Number of subjects: 18
Study 23466591 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate 10 g daily
Number of subjects: 18
Study 23466591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 20809859 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR)
Number of subjects: 40
Study 20809859 — intervention group
Group type: COMPARATOR
Intervention: Enamel Matrix Derivative (EMD)
Number of subjects: 40
Study 19298319 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 67
Study 19298319 — intervention group
Group type: COMPARATOR
Intervention: Alcohol education
Number of subjects: 67
Study 17056383 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine 2% gel
Number of subjects: 100
Study 17056383 — intervention group
Group type: COMPARATOR
Intervention: Subconjunctival lidocaine 2% injection
Number of subjects: 100
Study 14499424 — intervention group
Group type: EXPERIMENTAL
Intervention: Active laser exposure (Gallium‐Aluminum‐Arsenide laser)
Number of subjects: 24
Study 14499424 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser exposure
Number of subjects: 24
Study 14499424 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with chronic orofacial pain
Number of subjects: 24
Study 14499424 — intervention group
Group type: COMPARATOR
Intervention: Comparison between active laser and placebo
Number of subjects: 24
Study 10867305 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate, rent-free, abstinent-contingent housing during a 2-month Behavioral Day Treatment program
Number of subjects: 141
Study 10867305 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Day Treatment attendance
Number of subjects: 141
Study 10867305 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 141
Study 1703237 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavone acetic acid at doses less than or equal to 3.9 g/m2 administered intravenously over 1 hour
Number of subjects: 38
Study 1703237 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavone acetic acid at doses greater than or equal to 5.28 g/m2 administered over 6 hours
Number of subjects: 38
Study 1703237 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavone acetic acid at 10 g/m2
Number of subjects: 38
Study 1703237 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavone acetic acid at 8 g/m2 recommended for phase II
Number of subjects: 38
Study 6867755 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential MTX/5‐FU
Number of subjects: 0
Study 6867755 — intervention group
Group type: COMPARATOR
Intervention: Sequential 5‐FU/MTX
Number of subjects: 0
Study 6867755 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous MTX/5‐FU
Number of subjects: 0
Study 30273717 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP video intervention
Number of subjects: 328
Study 30273717 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ACP video)
Number of subjects: 328
Study 30273717 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic care preference
Number of subjects: 328
Study 30273717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive care preference
Number of subjects: 328
Study 29961606 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine (IIV)
Number of subjects: 0
Study 29961606 — intervention group
Group type: COMPARATOR
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 0
Study 26813483 — intervention group
Group type: EXPERIMENTAL
Intervention: Online cognitive behavioral therapy (CBT) delivered via email, 10 to 12 sessions conducted by a psychiatrist and a psychiatry resident.
Number of subjects: 93
Study 26813483 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 93
Study 24352960 — intervention group
Group type: EXPERIMENTAL
Intervention: DDGS at 0.5% of BW daily (DM basis)
Number of subjects: 70
Study 24352960 — intervention group
Group type: EXPERIMENTAL
Intervention: DDGS at 1% of BW daily (DM basis)
Number of subjects: 70
Study 24352960 — intervention group
Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 70
Study 21978965 — intervention group
Group type: EXPERIMENTAL
Intervention: Celivarone 300 mg once daily for 6 months
Number of subjects: 153
Study 21978965 — intervention group
Group type: EXPERIMENTAL
Intervention: Celivarone 300 mg once daily for 6 months (subgroup analysis)
Number of subjects: 153
Study 21978965 — intervention group
Group type: EXPERIMENTAL
Intervention: Celivarone (both dosages)
Number of subjects: 153
Study 21978965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 20451927 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.25-0.75 mg/day
Number of subjects: 141
Study 18046434 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (ACE-inhibitor)
Number of subjects: 62
Study 18046434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 15944885 — intervention group
Group type: EXPERIMENTAL
Intervention: Raising arm to overhead height task (hard task)
Number of subjects: 25
Study 15944885 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional tasks
Number of subjects: 25
Study 12444517 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional treatment (15 days strapping plus early controlled mobilization)
Number of subjects: 121
Study 12444517 — intervention group
Group type: COMPARATOR
Intervention: Cast immobilization (21 days plaster cast)
Number of subjects: 121
Study 10349576 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention program addressing sun protection, behavioral strategies, and structural changes over three years.
Number of subjects: 3
Study 10349576 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract).
Number of subjects: 3
Study 7862474 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse home visitation from pregnancy through the second year of the child's life
Number of subjects: 400
Study 7862474 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison children)
Number of subjects: 400
Study 2344111 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive outpatient treatment program
Number of subjects: 104
Study 2344111 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive outpatient treatment program (after crossover)
Number of subjects: 104
Study 2344111 — intervention group
Group type: COMPARATOR
Intervention: Previous outpatient care
Number of subjects: 104
Study 6424491 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate aerosol (2 mg four times daily)
Number of subjects: 48
Study 6424491 — intervention group
Group type: COMPARATOR
Intervention: Conventional powder (20 mg four times daily by Spinhaler)
Number of subjects: 48
Study 6424491 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate aerosol
Number of subjects: 48
Study 28872672 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Milieu Teaching (EMT) language intervention
Number of subjects: 97
Study 28872672 — intervention group
Group type: COMPARATOR
Intervention: Business as usual treatment
Number of subjects: 97
Study 29950252 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methotrexate 10 mg once weekly for eight weeks
Number of subjects: 100
Study 29950252 — intervention group
Group type: COMPARATOR
Intervention: Oral corticosteroids 40 mg daily for eight weeks, then tapered
Number of subjects: 100
Study 26888112 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 173
Study 26888112 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 173
Study 26888112 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength and endurance combined
Number of subjects: 173
Study 26888112 — intervention group
Group type: COMPARATOR
Intervention: Physical activity recommendations only
Number of subjects: 173
Study 26888112 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 173
Study 24467875 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based group-mediated cognitive behavioral walking intervention
Number of subjects: 194
Study 24467875 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 194
Study 24092823 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative octreotide treatment (n=28)
Number of subjects: 65
Study 24092823 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide treatment for 6 months
Number of subjects: 65
Study 24092823 — intervention group
Group type: COMPARATOR
Intervention: Direct surgery (n=13)
Number of subjects: 65
Study 24092823 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide pretreatment (n=13)
Number of subjects: 65
Study 21037456 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut fragrance
Number of subjects: 32
Study 21037456 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 32
Study 17882161 — intervention group
Group type: EXPERIMENTAL
Intervention: Laropiprant (single doses up to 900 mg)
Number of subjects: 3
Study 17882161 — intervention group
Group type: EXPERIMENTAL
Intervention: Laropiprant (multiple doses up to 450 mg)
Number of subjects: 3
Study 17882161 — intervention group
Group type: EXPERIMENTAL
Intervention: Laropiprant (single doses of 6 mg and higher)
Number of subjects: 3
Study 17882161 — intervention group
Group type: EXPERIMENTAL
Intervention: Laropiprant (multiple doses up to 200 mg)
Number of subjects: 3
Study 17882161 — intervention group
Group type: COMPARATOR
Intervention: Laropiprant
Number of subjects: 3
Study 16896684 — intervention group
Group type: EXPERIMENTAL
Intervention: DCT (PASCAL dynamic contour tonometer)
Number of subjects: 92
Study 16896684 — intervention group
Group type: COMPARATOR
Intervention: GAT (Goldmann applanation tonometry)
Number of subjects: 92
Study 16896684 — intervention group
Group type: EXPERIMENTAL
Intervention: DCT
Number of subjects: 92
Study 16896684 — intervention group
Group type: COMPARATOR
Intervention: GAT
Number of subjects: 92
Study 16896684 — intervention group
Group type: EXPERIMENTAL
Intervention: DCT and GAT
Number of subjects: 92
Study 12954255 — intervention group
Group type: EXPERIMENTAL
Intervention: Open carpal tunnel release with epineurotomy
Number of subjects: 273
Study 12954255 — intervention group
Group type: COMPARATOR
Intervention: Open carpal tunnel release without epineurotomy
Number of subjects: 273
Study 10440427 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg tablet)
Number of subjects: 15
Study 10440427 — intervention group
Group type: COMPARATOR
Intervention: Theophylline (300 mg capsule)
Number of subjects: 15
Study 8680375 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled bradykinin (8 mg.mL‐1)
Number of subjects: 4
Study 8680375 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled [desArg9]-bradykinin (8 mg.mL‐1)
Number of subjects: 4
Study 8680375 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 4
Study 1775780 — intervention group
Group type: EXPERIMENTAL
Intervention: Roles of oncology nurses in clinical trials (direct care provider, educator, advocate, data collector, primary investigator, member of the IRB)
Number of subjects: 0
Study 1775780 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse's role in informing subjects and facilitating decision making
Number of subjects: 0
Study 1775780 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse's role in protocol adherence and monitoring
Number of subjects: 0
Study 6811448 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisolone
Number of subjects: 20
Study 6811448 — intervention group
Group type: EXPERIMENTAL
Intervention: chloroquin
Number of subjects: 20
Study 6811448 — intervention group
Group type: EXPERIMENTAL
Intervention: clofazimine
Number of subjects: 20
Study 6811448 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 20
Study 30865075 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study 30865075 — intervention group
Group type: COMPARATOR
Intervention: General health education (Control)
Number of subjects: 0
Study 28882549 — intervention group
Group type: COMPARATOR
Intervention: Standard contraceptive counseling
Number of subjects: 361
Study 28882549 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling with information about IUD self-removal
Number of subjects: 361
Study 28882549 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (with and without self-removal information)
Number of subjects: 361
Study 26842107 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (starting at 15 mg daily for 2 weeks, increasing to 30 mg daily thereafter, for up to 12 months)
Number of subjects: 0
Study 26842107 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 0
Study 26842107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24290781 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-optimized group
Number of subjects: 423
Study 24290781 — intervention group
Group type: EXPERIMENTAL
Intervention: HR + Body-optimized group
Number of subjects: 423
Study 24290781 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 423
Study 24290781 — intervention group
Group type: EXPERIMENTAL
Intervention: HR-optimized group
Number of subjects: 423
Study 22931392 — intervention group
Group type: EXPERIMENTAL
Intervention: High importance (OR 2.94; 1.15, 7.50)
Number of subjects: 461
Study 22931392 — intervention group
Group type: EXPERIMENTAL
Intervention: High confidence (OR 2.88; 1.46, 5.68)
Number of subjects: 461
Study 22931392 — intervention group
Group type: EXPERIMENTAL
Intervention: High confidence (OR 3.29; 1.12, 9.62)
Number of subjects: 461
Study 22931392 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean readiness to change drinking scores: 3.9 (SD 3.0)
Number of subjects: 461
Study 22931392 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean importance to change drinking scores: 2.7 (SD 2.2)
Number of subjects: 461
Study 22931392 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean confidence to change drinking scores: 7.2 (SD 3.0)
Number of subjects: 461
Study 22931392 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean readiness to change smoking scores: 4.6 (SD 2.6)
Number of subjects: 461
Study 22931392 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean importance to change smoking scores: 5.3 (SD 2.6)
Number of subjects: 461
Study 22931392 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean confidence to change smoking scores: 5.9 (SD 2.7)
Number of subjects: 461
Study 22931392 — intervention group
Group type: EXPERIMENTAL
Intervention: 108 (29%) reported no unhealthy alcohol use at follow-up.
Number of subjects: 461
Study 22931392 — intervention group
Group type: EXPERIMENTAL
Intervention: 13% (33) reported no longer smoking at follow-up.
Number of subjects: 461
Study 21290832 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined laser group (n = 22)
Number of subjects: 41
Study 21290832 — intervention group
Group type: COMPARATOR
Intervention: Red light group (n = 19)
Number of subjects: 41
Study 17129220 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (sedation score of two)
Number of subjects: 10
Study 17129220 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (sedation score of two)
Number of subjects: 10
Study 17129220 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (sedation score of three)
Number of subjects: 10
Study 17129220 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (sedation score of three)
Number of subjects: 10
Study 17129220 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric dental pulp stimulation (invasive)
Number of subjects: 10
Study 17129220 — intervention group
Group type: EXPERIMENTAL
Intervention: Picture recall test (non‐invasive)
Number of subjects: 10
Study 15865615 — intervention group
Group type: EXPERIMENTAL
Intervention: Local electrostatic air cleaners
Number of subjects: 80
Study 15865615 — intervention group
Group type: COMPARATOR
Intervention: Non-functioning electrostatic unit (Control)
Number of subjects: 80
Study 11800220 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help group receiving additional multiple-contact telephone counseling
Number of subjects: 200
Study 11800220 — intervention group
Group type: COMPARATOR
Intervention: Standard self-help group
Number of subjects: 200
Study 9821992 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous esmolol
Number of subjects: 64
Study 9821992 — intervention group
Group type: COMPARATOR
Intervention: Intravenous diltiazem
Number of subjects: 64
Study 7648069 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a hand-held osmolality probe for hydration monitoring
Number of subjects: 28
Study 2473725 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% AA‐673 eye drops
Number of subjects: 11
Study 2473725 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 11
Study 324340 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge at 48 hours
Number of subjects: 0
Study 324340 — intervention group
Group type: COMPARATOR
Intervention: Discharge at 6-7 days
Number of subjects: 0
Study 324340 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge at 48 hours (hernia patients)
Number of subjects: 0
Study 324340 — intervention group
Group type: COMPARATOR
Intervention: Discharge at 6-7 days (hernia patients)
Number of subjects: 0
Study 30736951 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxidectin (MXD) 0.2 mg/kg SC
Number of subjects: 125
Study 30736951 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxidectin (MXD) 1.0 mg/kg SC
Number of subjects: 125
Study 30736951 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxidectin (MXD) 0.2 mg/kg IR
Number of subjects: 125
Study 30736951 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxidectin (MXD) 1.0 mg/kg IR
Number of subjects: 125
Study 30736951 — intervention group
Group type: COMPARATOR
Intervention: Ivermectin (IVM) 0.2 mg/kg SC
Number of subjects: 125
Study 30736951 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxidectin (MXD) (all groups)
Number of subjects: 125
Study 28150304 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid restriction
Number of subjects: 151
Study 28150304 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 151
Study 25407026 — intervention group
Group type: COMPARATOR
Intervention: Hartmann's solution (HS)
Number of subjects: 60
Study 23221674 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa
Number of subjects: 1
Study 23221674 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1
Study 21762232 — intervention group
Group type: EXPERIMENTAL
Intervention: Venner A.P. Advance (APA)
Number of subjects: 30
Study 21762232 — intervention group
Group type: COMPARATOR
Intervention: GlideScope Ranger (GSR)
Number of subjects: 30
Study 21762232 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 30
Study 20191820 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) therapy
Number of subjects: 70